Is It Time To Reconsider HealthEquity (HQY) After Recent Share Price Weakness

Simply Wall St.03-22

If you are wondering whether HealthEquity is attractively priced or if the opportunity has already passed, this article walks through the key numbers that matter for valuation. The stock last closed ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621918487?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6034000-choice1-main-header/1585187559063","is_english":true,"pubTime":"2026-03-22 03:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621918487","market":"hk","top_or_hot":-1,"title":"Is It Time To Reconsider HealthEquity (HQY) After Recent Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether HealthEquity is attractively priced or if the opportunity has already passed, this article walks through the key numbers that matter for valuation. The stock last closed ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/is-it-time-to-reconsider-healthequity-hqy-after-recent-share\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Reconsider HealthEquity (HQY) After Recent Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Reconsider HealthEquity (HQY) After Recent Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-22 03:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/is-it-time-to-reconsider-healthequity-hqy-after-recent-share><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether HealthEquity is attractively priced or if the opportunity has already passed, this article walks through the key numbers that matter for valuation. The stock last closed ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/is-it-time-to-reconsider-healthequity-hqy-after-recent-share\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169590202.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/is-it-time-to-reconsider-healthequity-hqy-after-recent-share","article_id":"2621918487","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6034000-choice1-main-header/1585187559063"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/is-it-time-to-reconsider-healthequity-hqy-after-recent-share","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621918487","pubTimestamp":1774120411,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether HealthEquity is attractively priced or if the opportunity has already passed, this article walks through the key numbers that matter for valuation.\nThe stock last closed at US$81.02, with returns of 4.1% over 7 days and 5.1% over 30 days. Year to date the return stands at an 11.0% decline and the 1-year return is a 4.5% decline, compared with a 44.6% gain over 3 years and 15.7% over 5 years.\nRecent headlines around HealthEquity have focused on its position in...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","HQY":"HealthEquity","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4154":"管理型保健护理","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"近期股价疲软后，是时候重新考虑HealthEquity(HQY)了吗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HQY":1.5,"DCF":1},"content_text":"If you are wondering whether HealthEquity is attractively priced or if the opportunity has already passed, this article walks through the key numbers that matter for valuation. The stock last closed at US$81.02, with returns of 4.1% over 7 days and 5.1% over 30 days. Year to date the return stands at an 11.0% decline and the 1-year return is a 4.5% decline, compared with a 44.6% gain over 3 years and 15.7% over 5 years. Recent headlines around HealthEquity have focused on its position in healthcare benefits administration and how the business fits into broader conversations about costs, access and digital tools in the sector. This context helps frame why shorter-term moves may look different to the multi-year return profile. HealthEquity currently holds a valuation score of 3 out of 6. The next sections will walk through what that means using different valuation approaches, before finishing with a broader way to think about what the numbers are really saying about the stock.  HealthEquity delivered -4.5% returns over the last year. See how this stacks up to the rest of the Healthcare industry. AdvertisementApproach 1: HealthEquity Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes the cash that a company is expected to generate in the future, then discounts each year’s figure back to today to estimate what the business might be worth right now. For HealthEquity, the 2 Stage Free Cash Flow to Equity model uses last twelve months free cash flow of about US$232.6 million as a starting point and then projects it forward. Analyst estimates extend to US$486.98 million of free cash flow in 2028, with further projections out to 2035 based on Simply Wall St assumptions. All of these future cash flows are discounted back to today in US$. Pulling this together, the model arrives at an estimated intrinsic value of about US$167 per share, compared with the recent share price of US$81.02. That gap implies the stock is around 51.5% undervalued on this DCF view. This represents a sizable difference for investors to weigh against their own expectations and risk tolerance. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests HealthEquity is undervalued by 51.5%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks. HQY Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for HealthEquity. Approach 2: HealthEquity Price vs Earnings For a profitable company, the P/E ratio is a useful way to relate what you pay per share to the earnings that support that price. A higher or lower P/E often reflects what the market is willing to pay for each dollar of earnings, given expectations and perceived risk. Growth expectations and risk both shape what might count as a “normal” or “fair” P/E. Faster expected earnings growth or lower perceived risk can justify a higher P/E, while slower growth or higher uncertainty can point to a lower one. HealthEquity currently trades on a P/E of 31.80x. That is above the Healthcare industry average of 21.22x and also above a peer group average of 17.28x. Simply Wall St’s Fair Ratio framework estimates what P/E might make sense for HealthEquity given factors such as its earnings growth profile, profit margins, industry, market cap and risk characteristics. This Fair Ratio for HealthEquity is 26.66x. The Fair Ratio can be more tailored than a simple peer or industry comparison because it adjusts for company specific drivers rather than just comparing raw multiples. With the current P/E of 31.80x above the Fair Ratio of 26.66x, the shares screen as overvalued on this metric. Result: OVERVALUED NasdaqGS:HQY P/E Ratio as at Mar 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies. Upgrade Your Decision Making: Choose your HealthEquity Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives are a simple way for you to attach a clear story about HealthEquity to your own numbers, linking assumptions about future revenue, earnings and margins to a financial forecast and then to a fair value that you can compare with the current price. On Simply Wall St’s Community page, Narratives are available as an easy tool that lets you test different viewpoints. For HealthEquity, that can mean one investor setting a higher fair value based on confidence in HSA market expansion, cost efficiencies and earnings growth, while another uses the same data to arrive at a lower fair value because they place more weight on risks such as interest rate dependency, healthcare cost pressures and competition. These Narratives stay useful because they update automatically when new information comes in, such as earnings guidance, analyst target changes or fresh commentary about growth, margins and discount rates. This allows you to quickly see whether your chosen fair value sits above or below the latest share price and decide whether that difference still fits your own view and risk tolerance. Do you think there's more to the story for HealthEquity? Head over to our Community to see what others are saying! NasdaqGS:HQY 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if HealthEquity might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621918487","isCrawlerRequest":true}